Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
13F holders, Q1 2022
Institutional positions in Gain Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −3 vs. Q4 2021
- Shares held
- 1.16M
- +106.0K (+10.0%) vs. Q4 2021
- Total value
- $4.75M
- −$959.0K (−16.8%) vs. Q4 2021
- New holders
- 1
- 6 more added
- Sold out
- 4
- 5 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 50 | $17.4M |
| Q1 2026 | 42 | $15.8M |
| Q4 2025 | 48 | $25.9M |
| Q3 2025 | 38 | $7.70M |
| Q2 2025 | 35 | $6.49M |
| Q1 2025 | 33 | $5.07M |
| Q4 2024 | 25 | $3.94M |
| Q3 2024 | 19 | $2.40M |
| Q2 2024 | 28 | $3.89M |
| Q1 2024 | 26 | $7.04M |
| Q4 2023 | 24 | $5.05M |
| Q3 2023 | 24 | $4.95M |
| Q2 2023 | 24 | $5.68M |
| Q1 2023 | 22 | $5.54M |
| Q4 2022 | 21 | $3.78M |
| Q3 2022 | 23 | $3.95M |
| Q2 2022 | 16 | $3.87M |
| Q1 2022 | 16 | $4.75M |
| Q4 2021 | 19 | $5.71M |
| Q3 2021 | 14 | $6.65M |
| Q2 2021 | 14 | $8.95M |
| Q1 2021 | 12 | $15.0M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Gain Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Greenlight Capital Inc | 546,560 | $2.24M | 0.14% | 00.0% | Unchanged |
| Telemetry Investments, L.L.C. | 240,000 | $979.0K | 1.57% | +88,868+58.8% | Added |
| CM Management, LLC | 125,000 | $511.0K | 0.43% | +35,000+38.9% | Added |
| Prelude Capital Management, LLC | 58,100 | $238.0K | 0.01% | 00.0% | Unchanged |
| Royal Bank of Canada | 50,000 | $205.0K | 0.00% | +39,440+373.5% | Added |
| Bridgeway Capital Management, LLC | 40,000 | $163.0K | 0.00% | −10,000−20.0% | Reduced |
| Geode Capital Management, LLC | 25,628 | $104.0K | 0.00% | +5,572+27.8% | Added |
| Veritable, L.P. | 25,064 | $103.0K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 11,722 | $48.0K | 0.00% | +11,722 | New |
| Millennium Management LLC | 10,808 | $44.0K | 0.00% | −4,946−31.4% | Reduced |
| BlackRock Inc. | 10,637 | $43.0K | 0.00% | −522−4.7% | Reduced |
| Advisor Group Holdings, Inc. | 10,050 | $41.0K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 4,100 | $17.0K | 0.00% | −6,397−60.9% | Reduced |
| Wells Fargo & Company | 2,673 | $11.0K | 0.00% | +2,650+11,521.7% | Added |
| Morgan Stanley | 803 | $3.00K | 0.00% | +3+0.4% | Added |
| Tower Research Capital LLC (TRC) | 593 | $2.00K | 0.00% | −577−49.3% | Reduced |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −19,467−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −19,357−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −13,029−100.0% | Sold out |
| Banque Cantonale Vaudoise | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |